Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	5.35B +1.2%
Revenue (ttm)	881.63M +8.5%
Net Income	294.76M +6.6%
EPS	3.72 +6.5%
Shares Out	78.31M
PE Ratio	18.36
Forward PE	n/a
Dividend	2.00 (2.93%)
Ex-Dividend Date	Oct 16, 2025

Volume	286,481
Average Volume	599,646
Open	69.18
Previous Close	69.23
Day's Range	68.26 - 69.45
52-Week Range	60.40 - 84.72
Beta	0.42
RSI	50.79
Earnings Date	Apr 20, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 960
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2024, Hangzhou Alltest Biotech's revenue was 866.58 million, an increase of 14.83% compared to the previous year's 754.70 million. Earnings were 302.47 million, an increase of 67.50%.